SecBot SecBot

Finn Sawyer Access to Cancer Testing Act

H.R. 1620 Rep. Doris Matsui (D-CA-7) In committee
Bill text PDF
  1. Introduced Feb 26
  2. Committee Feb 26
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 26, 2025Next: House vote
609d ago Feb 26, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Medical Devices & Healthcare 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Finn Sawyer Access to Cancer Testing Act

Full summary2 paragraphs

This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer.

Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.

Library of Congress summary, Feb 26, 2025

Summary versions
  • Introduced in HouseFeb 26, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.